A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas.

Authors:

Abstract
2029 Background: Treatment options for recurrent malignant glioma are limited. Preclinical activity of irinotecan has been seen in glioma models but only modest efficacy has been noted in clinical studies, perhaps related to drug distribution and/or pharmacokinetic limitations. In preclinical testing, liposomal irinotecan (nal-IRI, also MM-398, PEP02) demonstrates prolongation of drug exposure and higher tissue levels of drug due to slower metabolism. A Phase I study was undertaken in advanced solid tumor patients in Taiwan, and the MTD was 120 mg/m2; UGT1A1 genotyping was not prospectively undertaken in that solid tumor study. Objectives: To assess the safety and pharmacokinetics (PK) of nal-IRI and to determine the maximum tolerated dose (MTD) in patients with recurrent malignant glioma stratified based on UGT1A1 genotyping. Methods: This Phase I study in recurrent malignant glioma stratified patients by UGT1A1 status, to homozygous WT (“WT”) vs heterozygous WT/*28 (“HT”). Patients who were homozygous *...